Trial Profile
Role of a switch strategy to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate (QUAD) on HIV reservoir and immune activation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Sep 2019
Price :
$35
*
At a glance
- Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Emtricitabine; Tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Therapeutic Use
- 17 Sep 2019 Results published in the Clinical Drug Investigation
- 21 Aug 2015 New trial record